Athersys Inc (Athersys) is a biotechnology company focused on the development and discovery of regenerative medicines for the treatment of chronic, life-threatening diseases. The company's pipeline consists of therapeutic product development programs in multiple disease areas, through the application of proprietary technologies. Its lead programs are focused on the application of MultiStem, a patented and proprietary allogeneic stem cell product, used in developing regenerative drugs as a treatment for multiple disease indications.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Athersys conducts research to advance treatment for neurological, cardiovascular, certain pulmonary diseases, inflammatory, immune, and related diseases. The company is advancing MultiStem for neurological indications in Phase II clinical trials for the treatment of ischemic stroke and in the pre-clinical phase for the treatment of multiple sclerosis, hemorrhagic stroke, traumatic brain injury, and spinal cord injury. It is advancing its patented technology-based cardiovascular candidates in Phase II clinical trials for the treatment of acute myocardial infarction and in the pre-clinical phase for congestive heart failure, peripheral artery disease critical limb ischemia, and peripheral vascular disease. It harnesses its MultiStem technology for evaluating candidates for inflammatory, immune, and related diseases including two separate Phase II clinical trials for hematopoietic stem cell transplant (HSC) transplant or graft versus host disease (GvHD); and acute respiratory distress syndrome. It is also advancing the development of candidates for trauma and solid organ transplant support. In FY2021, the company spent US$71.1 million on its research and development expenses, which grew 12.8% YoY. The company holds more than 435 patents that offer protection for its technologies in the US, Europe, Japan, and others.